Beckman Coulter Life Sciences combines its particle characterization business with the Hach Company particle counting business.
Beckman Coulter Life Sciences, a Danaher Corporation-owned life science company, is combining its particle characterization business with the particle counting business from Hach Company, another Danaher company. The move brings together Beckman Coulter’s knowledge in cell viability, particle sizing, and particle analysis with Hach’s experience in air and liquid particle counting, according to a Beckman Coulter press statement.
In some countries, the transition is subject to completing consultation and/or information with certain employee representative bodies. Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work with the Beckman Coulter particle characterization team.
Source: Beckman Coulter Life Sciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.